SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. Financials Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Equities
6990
CNE1000062J1
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 177.5 HKD | +7.58% |
|
+5.78% | +72.50% |
Valuation
| Fiscal Period: December | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Capitalization 1 | 20,501 | 33,434 | - | - |
| Enterprise Value (EV) 2 | 19,042 | 32,859 | 32,660 | 32,458 |
| P/E ratio | -33.4 x | -58 x | -53.1 x | -359 x |
| Yield | - | - | - | - |
| Capitalization / Revenue | 13.3 x | 28.8 x | 21.9 x | 13.3 x |
| EV / Revenue | 12.4 x | 28.3 x | 21.4 x | 12.9 x |
| EV / EBITDA | -57.9 x | -59.3 x | -60.5 x | 135 x |
| EV / FCF | -839 x | -40.1 x | -84.3 x | -302 x |
| FCF Yield | -0.12% | -2.49% | -1.19% | -0.33% |
| Price to Book | - | 18.5 x | 28.3 x | 15.7 x |
| Nbr of stocks (in thousands) | 219,195 | 219,195 | - | - |
| Reference price 3 | 102.9 | 165.0 | 165.0 | 165.0 |
| Announcement Date | 3/25/24 | - | - | - |
1HKD in Million2CNY in Million3HKD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net sales 1 | - | 1,540 | 1,160 | 1,524 | 2,522 |
| EBITDA 1 | - | -328.6 | -554.4 | -540.1 | 240.5 |
| EBIT 1 | - | -383.4 | -661.1 | -721.5 | -279 |
| Operating Margin | - | -24.89% | -56.98% | -47.35% | -11.06% |
| Earnings before Tax (EBT) 1 | - | -467.7 | -590.8 | -608.2 | -35.38 |
| Net income 1 | -616.1 | -574.1 | -549.7 | -602.9 | -72.98 |
| Net margin | - | -37.27% | -47.38% | -39.56% | -2.89% |
| EPS 2 | -6.201 | -3.080 | -2.844 | -3.106 | -0.4599 |
| Free Cash Flow 1 | - | -22.69 | -818.8 | -387.2 | -107.3 |
| FCF margin | - | -1.47% | -70.57% | -25.41% | -4.26% |
| FCF Conversion (EBITDA) | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - |
| Announcement Date | 6/28/23 | 3/25/24 | - | - | - |
1CNY in Million2HKD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2023 S1 | 2023 S2 | 2024 S1 | 2024 S2 |
|---|---|---|---|---|
| Net sales 1 | 1,046 | 494.3 | 854.8 | 663 |
| EBITDA | - | - | - | - |
| EBIT 1 | 95.89 | - | -179 | -642.3 |
| Operating Margin | 9.17% | - | -20.94% | -96.88% |
| Earnings before Tax (EBT) | - | - | - | - |
| Net income | - | - | - | - |
| Net margin | - | - | - | - |
| EPS 2 | -0.1829 | -2.896 | -1.170 | -3.270 |
| Dividend per Share | - | - | - | - |
| Announcement Date | 8/28/23 | 3/25/24 | - | - |
1CNY in Million2HKD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - |
| Net Cash position 1 | - | 1,459 | 575 | 774 | 975 |
| Leverage (Debt/EBITDA) | - | - | - | - | - |
| Free Cash Flow 1 | - | -22.7 | -819 | -387 | -107 |
| ROE (net income / shareholders' equity) | - | - | -29.2% | -67.9% | -7.97% |
| ROA (Net income/ Total Assets) | - | -25.5% | -25.5% | -27.5% | 7.2% |
| Assets 1 | - | 2,251 | 2,158 | 2,196 | -1,014 |
| Book Value Per Share 2 | - | - | 8.940 | 5.820 | 10.50 |
| Cash Flow per Share 2 | - | 0.3500 | -2.900 | -0.2200 | 4.910 |
| Capex 1 | - | 82.3 | 161 | 151 | 152 |
| Capex / Sales | - | 5.34% | 13.86% | 9.93% | 6.02% |
| Announcement Date | 6/28/23 | 3/25/24 | - | - | - |
1CNY in Million2HKD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
165
HKD
Average target price
184
HKD
Spread / Average Target
+11.54%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +72.50% | 4.63B | |
| +2.93% | 108B | |
| -3.55% | 23.46B | |
| -14.60% | 21.72B | |
| -7.05% | 18.64B | |
| -38.55% | 17.45B | |
| -8.83% | 17.19B | |
| +5.51% | 13.99B | |
| +37.49% | 12.53B | |
| +329.39% | 8.81B |
- Stock Market
- Equities
- 6990 Stock
- Financials Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.